ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

FULC Fulcrum Therapeutics Inc

7.55
-0.245 (-3.14%)
18 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Fulcrum Therapeutics Inc NASDAQ:FULC NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.245 -3.14% 7.55 7.40 7.73 7.75 7.45 7.75 480,460 00:54:55

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Fulcrum Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 27, 2023 - (NASDAQ: FULC)

10/05/2023 10:45am

PR Newswire (US)


Fulcrum Therapeutics (NASDAQ:FULC)
Historical Stock Chart


From May 2022 to May 2024

Click Here for more Fulcrum Therapeutics Charts.

NEW YORK, May 10, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Fulcrum Therapeutics, Inc..

Shareholders who purchased shares of FULC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/fulcrum-loss-submission-form/?id=39135&from=4

CLASS PERIOD: March 3, 2022 to March 8, 2023

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the preclinical data submitted in support of FTX-6058 (an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies) showed safety concerns regarding potential hematological malignancies; (ii) the foregoing safety concerns increased the likelihood that the FDA would place a clinical hold on preclinical studies of FTX-6058; (iii) accordingly, the Company had overstated FTX-6058's clinical and/or commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

DEADLINE: June 27, 2023 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/fulcrum-loss-submission-form/?id=39135&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of FULC during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is June 27, 2023. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903

Cision View original content:https://www.prnewswire.com/news-releases/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-fulcrum-therapeutics-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-june-27-2023--nasdaq-fulc-301820356.html

SOURCE The Gross Law Firm

Copyright 2023 PR Newswire

1 Year Fulcrum Therapeutics Chart

1 Year Fulcrum Therapeutics Chart

1 Month Fulcrum Therapeutics Chart

1 Month Fulcrum Therapeutics Chart